• LAST PRICE
    27.8000
  • TODAY'S CHANGE (%)
    Trending Up0.0500 (0.1802%)
  • Bid / Lots
    27.7700/ 1
  • Ask / Lots
    27.8300/ 2
  • Open / Previous Close
    28.0000 / 27.7500
  • Day Range
    Low 27.7200
    High 28.7400
  • 52 Week Range
    Low 16.4100
    High 34.4350
  • Volume
    834,978
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Friday's close: 27.75
TimeVolumeINSM
09:32 ET1888428.045
09:34 ET2281228.035
09:36 ET2956827.725
09:38 ET1636327.8
09:39 ET1315828.32
09:41 ET1204728.22
09:43 ET640028.33
09:45 ET1855728.49
09:48 ET1979928.57
09:50 ET2739628.64
09:52 ET5829528.575
09:54 ET1273428.13
09:56 ET274628.09
09:57 ET993828.22
09:59 ET1543428.3
10:01 ET6696728.46
10:03 ET1991428.52
10:06 ET1231128.43
10:08 ET13088128.375
10:10 ET3738528.33
10:12 ET786428.065
10:14 ET1690928.175
10:15 ET10991628.02
10:17 ET1164927.84
10:19 ET1748527.8
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesINSM
Insmed Inc
3.3B
-7.9x
---
United StatesGMAB
Genmab A/S
23.1B
71.3x
---
United StatesFOLD
Amicus Therapeutics Inc
3.4B
-12.6x
---
United StatesFATE
Fate Therapeutics Inc
3.2B
-13.6x
---
United StatesTWST
Twist Bioscience Corp
3.0B
-15.1x
---
United StatesVSBC
Vitaspring Biomedical Co. Ltd
3.4B
2,492.4x
---
As of 2022-08-08

Company Information

Insmed Incorporated is a biopharmaceutical company engaged in providing ARIKAYCE (amikacin liposome inhalation suspension) product, which is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its clinical-stage pipeline includes brensocatib and treprostinil palmitil inhalation powder (TPIP). Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1, which is developing for the treatment of patients with bronchiectasis, cystic fibrosis (CF) and other neutrophil-mediated diseases, including chronic rhinosinusitis without nasal polyps (CRS) and hidradenitis suppurativa (HS). TPIP is an inhaled formulation of the treprostinil prodrug treprostinil palmitil which may offer a differentiated product profile for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Contact Information

Headquarters
700 Us Highway 202/206BRIDGEWATER, NJ, United States 08807
Phone
908-977-9900
Fax
---

Executives

Chairman of the Board, President, Chief Executive Officer
William Lewis
Chief Financial Officer
Sara Bonstein
Chief Operating Officer
Roger Adsett
Chief People Strategy Officer
S. Nicole Schaeffer
Senior Vice President, General Counsel
Michael Smith

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$3.3B
Revenue (TTM)
$221.2M
Shares Outstanding
119.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.88
EPS
$-3.51
Book Value
$3.46
P/E Ratio
-7.9x
Price/Sales (TTM)
15.0
Price/Cash Flow (TTM)
---
Operating Margin
-172.16%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.